Sagimet raises $120M to push acne drug into Phase 3
What's the deal? Sagimet Biosciences (Nasdaq: SGMT) has priced a $115 million underwritten public offering, selling Series A common stock at $10.00 per share alongside pre-funded warrants. The financing is led by Commodore CapitalDealroom has a profile for this one. Try Dealroom →, with participation from RA Capital Management, Spruce Street CapitalDealroom has a profile for this one. Try Dealroom →, BVF PartnersDealroom has a profile for this one. Try Dealroom →, Aberdeen Investments, Columbia Threadneedle InvestmentsDealroom has a profile for this one. Try Dealroom →, Affinity Asset AdvisorsDealroom has a profile for this one. Try Dealroom →, and Woodline PartnersDealroom has a profile for this one. Try Dealroom →.
Why now? The Foster City, California-based company is a clinical-stage biopharmaceutical firm developing FASN inhibitors that target metabolic and fibrotic disease pathways. The fresh capital arrives as it prepares to move its lead candidate into late-stage testing. The offering is expected to close on or about October 1, 2026.
What's the endgame? Sagimet plans to use the proceeds, with existing cash, to fund a Phase 3 trial of denifanstat in acne and pre-launch activities for the drug. It will also advance TVB-3567 through Phase 2 topline results and push its topical FASN inhibitor toward an IND submission.
The company sold 8,750,010 shares plus warrants to purchase 2,750,010 more, with warrants carrying an exercise price of $0.0001 and exercisable immediately. Leerink PartnersDealroom has a profile for this one. Try Dealroom →, TD CowenDealroom has a profile for this one. Try Dealroom →, Guggenheim SecuritiesDealroom has a profile for this one. Try Dealroom →, and Oppenheimer & Co.Dealroom has a profile for this one. Try Dealroom → acted as joint bookrunning managers.
What could go wrong? The proceeds hinge on clinical outcomes. Denifanstat still faces a Phase 3 readout, and any setback in the acne trial or the earlier-stage programmes would leave the capital chasing uncertain milestones.
The signal: A $115 million raise puts Sagimet in the upper tier of recent funding events, a sign that specialist healthcare investors remain willing to back clinical-stage biotech with a clear late-stage path. Commodore Capital's lead role, joined by well-known crossover names like RA Capital and BVF, points to sustained institutional appetite for FASN-targeting therapeutics.
Read more: pr.lakeoconeebreeze.net
Image credit: zhouxuan12345678
